NVS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Considering the investor's beginner level, long-term preference, and available capital, Novartis AG (NVS) is not a strong buy at the moment. While there are positive developments in its pipeline and WHO prequalification for Coartem Baby, the technical indicators and financial performance suggest a cautious approach. The stock is better suited for monitoring until stronger entry signals or improved financial trends emerge.
The MACD is negatively expanding (-0.448), RSI is neutral at 29.418, and moving averages are converging. The stock is trading near its support level (S1: 147.554, S2: 145.222) with pre-market price at 145.61 (-1.27%). This suggests a bearish short-term trend.
WHO prequalification for Coartem Baby, addressing a significant treatment gap in malaria treatment for newborns and young infants. Analysts have raised price targets, citing strong pipeline assets like remibrutinib and other key drugs.
Declining financial metrics in Q4 2025, including a 14.51% drop in net income and an 11.43% drop in EPS. Technical indicators suggest a bearish trend. No significant hedge fund or insider trading activity.
In Q4 2025, revenue increased by 2.23% YoY to $13.86B, but net income dropped by 14.51% YoY to $2.41B. EPS fell by 11.43% YoY to 1.24, and gross margin decreased slightly to 74.44%.
Analysts are generally positive, with multiple upgrades and price target increases. Morgan Stanley raised the target to $170, BofA to $178, and Argus to $180, citing strong pipeline assets and attractive entry points. However, Bernstein and HSBC remain cautious, citing long-term sales declines and macro risks.
